Clinical trials in Genk – page 51

1 420 clinical trials in Genk, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Genk at a glance

1 420

clinical trials

Research sites1

Quick filters

1 420 trials in Genk

Open in trial search

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Hopital Erasme

Contact Research Centre

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

Belgium

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Interstitial lung disease+1

Not yet recruiting

A Phase 2 Study Evaluating the Safety and Efficacy of Oral NS-863 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational

A Phase 2 Study Evaluating the Safety and Efficacy of Oral NS-863 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:NS-863
Sponsor:Ns Pharma Inc.

Contact Research Centre

Paroxysmal nocturnal haemoglobinuria

Not yet recruiting

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Sponsor:Bisirna Therapeutics Pte. Ltd.

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Efimosfermin alfa
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Efimosfermin alfa
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Contact Research Centre

IgA nephropathy

Not yet recruiting

Study of ARGX-121 to Reduce Proteinuria in Adults with Primary IgA Nephropathy (IgAN)

Investigational

Study of ARGX-121 to Reduce Proteinuria in Adults with Primary IgA Nephropathy (IgAN)

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:ARGX-121
Sponsor:Argenx

Contact Research Centre

Crohn's disease

Not yet recruiting

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Registered drugNo placebo

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Upadacitinib
Sponsor:UZ Leuven

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Genk

What the registry says about research in the country

01 Respiratory Disease Trials

Extensive research focusing on respiratory syncytial virus (RSV) and influenza prevention in older adults. Studies evaluate innovative vaccine combinations and immune responses in participants over 60 years.

RSV and human metapneumovirus vaccines
High-dose Influenza vaccines
Vaccine co-administration studies

Multiple trials aim to enhance protection against respiratory infections in vulnerable populations.

02 Cardiovascular Research

Comprehensive studies addressing various aspects of heart disease and related conditions, including innovative treatments for hypertrophic cardiomyopathy and heart failure.

Acute Heart Failure treatments
Pulmonary Hypertension therapies
Cardiovascular disease prevention

Trials explore new therapeutic approaches for managing complex cardiac conditions.

03 Autoimmune Conditions

Clinical research examining treatments for various autoimmune disorders, including innovative therapies for rheumatoid arthritis and Sjögren's syndrome.

Psoriatic Arthritis treatments
Rheumatoid Arthritis therapies
Primary Sjögren's Disease interventions

Studies focus on improving treatment outcomes and quality of life for patients with autoimmune conditions.

Back to Belgium All countries